
John A Vest MD
Cardiac Electrophysiology
Assistant Professor, Medicine, Columbia University College of Phys &
Join to View Full Profile
New York Presbyterian Hospital630 West 168th Street, Ph3-347New York, NY 10032
Phone+1 212-305-8194
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Vest, MD is a cardiologist in New York, New York. He is an Assistant Professor at Columbia University College of Phys &.
Education & Training
Mass General Brigham/Brigham and Women's HospitalFellowship, Clinical Cardiac Electrophysiology, 2006 - 2007
New York Presbyterian Hospital(Cornell Campus)/Coney Island HospitalFellowship, Cardiovascular Disease, 2002 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2002
Columbia University Vagelos College of Physicians and SurgeonsClass of 1998
Publications & Presentations
PubMed
- 8 citationsDevelopment of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum.Sharmila Dorbala, Rosalyn Adigun, Kevin M Alexander, Michela Brambatti, Sarah A M Cuddy
JACC. Cardiovascular Imaging. 2025-05-01 - 236 citationsVutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.Marianna Fontana, John L Berk, Julian D Gillmore, Ronald M Witteles, Martha Grogan
The New England Journal of Medicine. 2025-01-02 - 40 citationsImpact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.Pablo Garcia-Pavia, Martha Grogan, Parag Kale, John L Berk, Mathew S Maurer
European Journal of Heart Failure. 2024-02-01
Press Mentions
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with VutrisiranSeptember 28th, 2025
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual MeetingJune 7th, 2021
FDA Panel Supports Patisiran for ATTR Amyloidosis with CardiomyopathySeptember 15th, 2023









